Experimental allergic encephalomyelitis-prophylactic and therapeutic treatment with the cyclooxygenase inhibitor piroxicam (Feldene).
Prophylactic administration of Piroxicam (Feldene), a reversible inhibitor of prostaglandin biosynthesis, significantly reduced the occurrence of paralytic signs and the amount of antibodies against myelin basic protein in the model of mild acute experimental allergic encephalomyelitis in the Lewis rat. Mononuclear infiltration of the central nervous system remained unaffected. A therapeutic intervention with piroxicam, however, increased paresis and CNS pathology. Immunohistochemical studies revealed an increased proportion of ED1-positive macrophages and monocytes in the infiltrates of the spinal cord in animals treated with piroxicam. Possible reasons for the different effects of the prophylactic and therapeutic treatment are discussed in the study.
Institute of Medical Radiation Research, University of Würzburg, FRG.
F
F
Weber
R
R
Meyermann
K
K
Hempel
D000284:Administration, Oral; D000818:Animals; D004305:Dose-Response Relationship, Drug; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy* / Q000517:prevention & control; D007274:Injections, Intraperitoneal; D007958:Leukocyte Count / Q000187:drug effects; D008264:Macrophages; D009000:Monocytes; D010894:Piroxicam / Q000493:pharmacokinetics / Q000627:therapeutic use*; D051381:Rats; D011917:Rats, Inbred Lew
D010894:Piroxicam